New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients

Table 2 Median overall survival (OS) after recurrence according to patient characteristics

Characteristics	All		Single metastasis		Multiple metastases
Characteristics	Median OS (year)	p-value	Median OS (year)	p-value	Median OS (year)	p-value
All patients	4.58		5.86		2.50	< 0.001
Stage at diagnosis		0.195		0.840		0.073
I + II	4.60		6.30		2.53
III	3.79		5.30		1.78
Adjuvant chemotherapy		0.446		0.149		0.613
Yes	4.44		5.46		2.50
No	5.55		7.56		2.35
Age at recurrence		0.972		0.259		0.596
< 50y	3.52		4.54		2.39
≥ 50y	4.67		6.81		2.50
DFI		< 0.001		< 0.001		< 0.001
< 2 years	2.17		3.03		1.35
≥ 2 years	5.33		7.68		3.26
CEA/CA15–3 serum level		< 0.001		0.014		0.390
Normal	8.20		8.20		3.54
High	3.26		4.83		2.49
Initial therapy for reccurence		0.077		0.348		0.524
Endocrine therapy	5.46		6.30		2.53
Chemotherapy	3.12		5.30		2.50
Distribution pattern in single metastasis				< 0.001
Diffuse lesions	–		4.60		–
Non-diffuse lesions	–		11.83		–
Metastatic organ site
Bone	4.51 (vs. 4.83)	0.443	5.86 (vs. 6.30)	0.869	1.96 (vs. 3.26)	0.327
Lymph node	3.54 (vs. 5.46)	0.022	4.54 (vs. 7.56)	0.088	2.57 (vs. 2.20)	0.279
Lung	5.72 (vs. 4.54)	0.688	8.20 (vs. 5.46)	0.062	2.50 (vs. 2.44)	0.287
Liver	1.96 (vs. 5.30)	< 0.001	9.13 (vs. 5.72)	0.670	1.88 (vs. 3.87)	< 0.001
Pleura	3.54 (vs. 4.73)	0.204	2.90 (vs. 6.30)	0.153	3.54 (vs. 2.39)	0.254
Brain	0.800 (vs. 4.67)	< 0.001	–	–	0.800 (vs. 2.50)	0.027

ISSN: 1471-2407